Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency
Vanessa A Evans,Renée M van der Sluis,Ajantha Solomon,Ashanti Dantanarayana,Catriona McNeil,Roger Garsia,Sarah Palmer,Rémi Fromentin,Nicolas Chomont,Rafick-Pierre Sékaly,Paul U Cameron,Sharon R Lewin,Dantanarayana, Ashanti,McNeil, Catriona,Solomon, Ajantha,Fromentin, Rémi,van der Sluis, Renée M.,Sékaly, Rafick-Pierre,Evans, Vanessa A.,Chomont, Nicolas,Cameron, Paul U.,Palmer, Sarah,Garsia, Roger,Lewin, Sharon R.
DOI: https://doi.org/10.1097/QAD.0000000000001849
IF: 4.632
2019-10-03
AIDS
Abstract:Objective:
In HIV-infected individuals on antiretroviral therapy (ART), latent HIV is enriched in CD4+ T cells expressing immune checkpoint molecules, in particular programmed cell death-1 (PD-1). We therefore assessed the effect of blocking PD-1 on latency, both in vitro and in vivo.
Methods:
HIV latency was established in vitro following coculture of resting CD4+ T cells with myeloid dendritic cells. Expression of PD-1 was quantified by flow cytometry, and latency assessed in sorted PD-1high and PD-1low/− nonproliferating CD4+ memory T cells. The role of PD-1 in the establishment of latency was determined by adding anti-PD-1 (pembrolizumab) to cocultures before and after infection. In addition, a single infusion of anti-PD-1 (nivolumab) was administered to an HIV-infected individual on ART with metastatic melanoma, and cell-associated HIV DNA and RNA, and plasma HIV RNA were quantified.
Results:
HIV latency was significantly enriched in PD-1high compared with PD-1low/- nonproliferating, CD4+ memory T cells. Sorting for an additional immune checkpoint molecule, T-cell immunoglobulin domain and mucin domain-3, in combination with PD-1, further enriched for latency. Blocking PD-1 prior to HIV infection, in vitro, resulted in a modest but significant decrease in latently infected cells in all donors (n = 6). The administration of anti-PD-1 to an HIV-infected individual on ART resulted in a significant increase in cell-associated HIV RNA in CD4+ T cells, without significant changes in HIV DNA or plasma HIV RNA, consistent with reversal of HIV latency.
Conclusion:
PD-1 contributes to the establishment and maintenance of HIV latency and should be explored as a target, in combination with other immune checkpoint molecules, to reverse latency.
immunology,infectious diseases,virology